Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gabriel

Showing results (141-150 of 154) with videos related to

Pageof 16
Sort By:
Bone Marrow Transplantation|October 12, 2011
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSFG W Basak, W Wiktor-Jedrzejczak, J F Apperley, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|March 23, 2013
Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitorsGiuseppe De Luca, Michael C Gibson, Arnoud W J Van't Hof, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 18, 2011
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomideFlorent Malard, Nicolaus Kröger, Ian H Gabriel, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 14, 2018
Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignanciesJulie Beckerson, Richard M Szydlo, Mary Hickson, et al.
Bone Marrow Transplantation|November 15, 2011
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilizationK Hübel, M M Fresen, J F Apperley, et al.
Blood|July 24, 2012
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemiaSara Ali, Ruhena Sergeant, Stephen G O'Brien, et al.
Circulation. Cardiovascular Interventions|September 17, 2025
Prospective Multicenter IDE Study of the Next-Generation Precision Aspiration Thrombectomy System for Intermediate-Risk Pulmonary Embolism: The SYMPHONY-PE TrialSripal Bangalore, R Dana Tomalty, Herman Kado, et al.
Circulation. Cardiovascular Interventions|June 18, 2026
Is There a Golden Hour for Thrombectomy in Intermediate-Risk Pulmonary Embolism? Insights From SYMPHONY-PESripal Bangalore, R Dana Tomalty, Herman Kado, et al.
Nature Communications|June 19, 2021
Live-cell imaging of circadian clock protein dynamics in CRISPR-generated knock-in cellsChristian H Gabriel, Marta Del Olmo, Amin Zehtabian, et al.
The American Journal of Gastroenterology|August 10, 2023
Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular CarcinomaYee Hui Yeo, Jeff Liang, Marie Lauzon, et al.
Pageof 16

Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Bone Marrow Transplantation|October 12, 2011
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSFG W Basak, W Wiktor-Jedrzejczak, J F Apperley, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|March 23, 2013
Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitorsGiuseppe De Luca, Michael C Gibson, Arnoud W J Van't Hof, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 18, 2011
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomideFlorent Malard, Nicolaus Kröger, Ian H Gabriel, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 14, 2018
Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignanciesJulie Beckerson, Richard M Szydlo, Mary Hickson, et al.
Bone Marrow Transplantation|November 15, 2011
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilizationK Hübel, M M Fresen, J F Apperley, et al.
Blood|July 24, 2012
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemiaSara Ali, Ruhena Sergeant, Stephen G O'Brien, et al.
Circulation. Cardiovascular Interventions|September 17, 2025
Prospective Multicenter IDE Study of the Next-Generation Precision Aspiration Thrombectomy System for Intermediate-Risk Pulmonary Embolism: The SYMPHONY-PE TrialSripal Bangalore, R Dana Tomalty, Herman Kado, et al.
Circulation. Cardiovascular Interventions|June 18, 2026
Is There a Golden Hour for Thrombectomy in Intermediate-Risk Pulmonary Embolism? Insights From SYMPHONY-PESripal Bangalore, R Dana Tomalty, Herman Kado, et al.
Nature Communications|June 19, 2021
Live-cell imaging of circadian clock protein dynamics in CRISPR-generated knock-in cellsChristian H Gabriel, Marta Del Olmo, Amin Zehtabian, et al.
The American Journal of Gastroenterology|August 10, 2023
Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular CarcinomaYee Hui Yeo, Jeff Liang, Marie Lauzon, et al.
Pageof 16